Fifth Third Bancorp trimmed its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 1.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,410,470 shares of the biopharmaceutical company's stock after selling 39,491 shares during the period. Fifth Third Bancorp's holdings in Pfizer were worth $66,891,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors also recently added to or reduced their stakes in the stock. Briaud Financial Planning Inc bought a new position in shares of Pfizer during the 3rd quarter worth approximately $30,000. Mizuho Securities Co. Ltd. purchased a new stake in shares of Pfizer in the 3rd quarter valued at $34,000. VisionPoint Advisory Group LLC boosted its holdings in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 1,047 shares during the last quarter. GoalVest Advisory LLC boosted its holdings in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company's stock valued at $31,000 after acquiring an additional 811 shares during the last quarter. Finally, Creekmur Asset Management LLC acquired a new stake in Pfizer during the fourth quarter valued at $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
PFE has been the topic of several research analyst reports. Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a "buy" rating and a $36.00 target price on the stock. Morgan Stanley lifted their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an "equal weight" rating in a research note on Thursday. Argus downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Friday, March 22nd. BMO Capital Markets reissued an "outperform" rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a research note on Thursday. Finally, TD Cowen cut shares of Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 price objective for the company. in a report on Thursday, January 4th. Eleven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $36.00.
Read Our Latest Stock Report on PFE
Pfizer Stock Up 1.9 %
Shares of NYSE:PFE traded up $0.52 during trading on Thursday, hitting $27.70. 63,855,289 shares of the company were exchanged, compared to its average volume of 42,875,957. The stock has a market capitalization of $156.85 billion, a P/E ratio of 76.94, a PEG ratio of 1.15 and a beta of 0.63. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $40.37. The firm's 50 day moving average price is $26.88 and its 200-day moving average price is $28.25.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company's revenue was down 19.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.23 EPS. On average, research analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.
Pfizer Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.06%. Pfizer's dividend payout ratio (DPR) is 466.67%.
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
